Stephen M. Dow

Reactive NanoTechnologies, Inc. develops and manufactures nanofoil technologies for reaction initiation and joining applications. Its products are used in armor mounting, structural joining, component mounting, sealing, sputtering targets joining, and thermal interface material applications. The firm offers services to the energetics, semiconductor, and military aerospace industries. The company was founded in 2001 and is headquartered in Hunt Valley, MD.

Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities.

Calera Corp. converts carbon dioxide into minerals or other usable materials. It is a clean technology start-up company that is focused on CO2 reduction through both capture and conversion to products and low energy production of industrial chemicals. Calera's core technology converts captured carbon dioxide from industrial plants, and converts the CO2 to carbonate cements that have a large range of applications. The company was founded by Brent R. Constantz in 2007 and is headquartered in Los Gatos, CA.

Arterys, Inc. develops clinical 4D flow MRI platform to radically improve the process of diagnosing and staging cardiovascular disease. It offers ultra-fast visualization, and ultra-fast quantification services. The company was founded by Fabien Beckers, John Axerio-Cilies, Shreyas Vasanawala and Albert Hsiao in 2007 and is headquartered in San Francisco, CA.

Dataminr, Inc. provides social media analytics services. It offers a solution that transforms the public twitter stream into actionable alerts, identifying the most relevant information in real-time for clients in finance, news and the public sector. The company was founded by Edward J. Bailey, Jeffrey Kinsey and Samuel Lifton Hendel in 2009 and is headquartered in New York, NY.